Betamethasone 0.1% and clioquinol 3%

Betnovate-C Cream – the effective preparation for treating fungal and/or secondary bacterial infection
Betnovate-C Cream is anti-inflammatory, anti-allergic and antipruritic remedy for outward application

Betnovate

 

Betnovate-C Cream. Formula

Betnovate-C Cream is a skin preparation, which contains betamethasone 0.1% and clioquinol 3%. It is a straw-colored, water-miscible, paraffin-based ointment.

 
Betnovate-C Cream. What diseases does the preparation treat?
This preparation is put on to prevent and treat fungal and/or secondary bacterial infection:

–    Anal and genital intertrigo.
–    Contact sensitivity reactions.
–    Eczema including atopic, discoid and infantile eczemas.
–    Insect bite reactions.
–    Neuro-dermatoses, which include lichen planus and lichen simplex.
–    Otitis externa.
–    Prickly heat.
–    Prurigo nodularis.
–    Psoriasis (excluding the kind which is called widespread plaque psoriasis).
–    Seborrhoeic dermatitis.

 
Betnovate-C Cream. How to take?

A minute quantity of Cream should be laid on the affected area twice or three times every day until a patient feels significant improvements. Then to control the improvement use the preparation once per day or even less often.

Before applying Cream, dab the affected area with the help of the wet sanitary wipe.

In the case, if you suffer from the thickened plaques of psoriasis on the elbows and knees, the effect of the treatment can be enhanced, by occluding the area of treatment with polythene film.

Usually overnight occlusion is adequate to bring about a satisfactory effect in such lesions, thereafter, as a rule, the improvement occurs by constant application without occlusion.

 
Betnovate-C Cream . What are the contraindications for applying the preparation?

a) Acne vulgaris.
b) Hypersensitivity to any preparation’s component or to iodine.
c) Perianal or genital pruritus.
d) Oral dermatitis.
e) Primary cutaneous viral infections (for example, herpes simplex, chickenpox).
f) Rosacea.
Use of this preparation is not put on to treat skin lesions of primary infection, which have been caused by bacterial or fungal infections; primary or secondary infections due to yeast; dermatosis in children under one year of age, including dermatitis and eruptions.
The use of the product in the eyes is contraindicated.

 
Betnovate-C Cream. Special Warnings and Precautions

Long-term topical therapy has to be avoided in those cases when it is possible, particularly in children, especially infants, as adrenal suppression may occur even without any occlusion. Systemic absorption and hypothalamic-pituitary axis suppression may occur.

Use for longer than 4 weeks can cause atrophic striae, prolonged use on sentinel piles and in intertriginous areas is undesirable.

The face, more than other areas of s body, can exhibit the atrophic changes after continuous treatment with potent topical corticosteroids. This must be kept in mind during the treatment period of such states as discoid lupus erythematosus, psoriasis, and severe eczema.

If Betnovate-C Cream is laid on the skin around the eyelids, you have to care that the preparation does not fall in the eye, because it may cause glaucoma.

If you use the preparation to treat psoriasis, be very careful while using the product.

This cream may stain any surface: hair, fabric or skin, and the application should be covered with any dressing to protect clothing.

The patients should not use any products containing antimicrobial agents, while using Betnovate-C Cream

The cream is not expected to have any harmful effect on ability to drive a car and use any other kinds of machines.

 
Betnovate-C Cream. Overdose

Acute overdosing is very unlikely to occur, however, if there is overdose or misuse, the features of hypercortisolism may appear and the treatment has to be discontinued under medical supervision because of the great risk of the adrenal insufficiency’s development.

Be the first to comment on "Betamethasone 0.1% and clioquinol 3%"

Leave a comment

Your email address will not be published.


*